Figure 1.
Factors influencing the formulation properties of RSV-PLGA-NPs. (a) 50 mg PLGA versus 8 mg RSV, 4 h of stirring time; (b) 50 mg PLGA versus 10 mg RSV, 10 ml of BSA solution, 4 h of stirring time; (c) 50 mg PLGA versus 10 ml of BSA solution, 4 h of stirring time; (d) 50 mg PLGA versus 9 mg RSV, 10 ml of BSA solution.